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ABSTRACT 
Radiotherapy is a widely used method to treat malignant tumors. However, the 
sensitivity to the treatment varies between tumors, and local tumor control is not always 
achieved. The balance between treatment success and the side effects of the treatment 
affords important information for developing treatment schedules at patient population 
level. Conversely there are no methods to tailor treatment schedules in an individual 
patient in clinical practice. The purpose of such methods would be to better balance 
treatment success with side effects in the individual, hopefully avoiding unnecessary 
treatments. As some tumors are resistant to radiotherapy doses that may be delivered 
without severe side effects, finding methods to sensitize tumor cells is of major 
importance. 
 
In Paper I we evaluated a radiobiology model for predicting surviving fraction (SF) in 
five lung cancer cell lines. The purpose was to see whether it was important to include 
tumor cell proliferation during fractionated radiotherapy in a predicting radiobiology 
formula based on radiosensitivity, proliferation and number of tumor cells. When the 
clonogenic assay is used to establish SF, including proliferation seems to predict SF 
after fractionated radiation better than using inherent radiosensitivity alone. 
In Paper II we evaluated the same radiobiology model in a clinical material of head 
and neck carcinomas. In 18 patients we compared using patient-specific radiobiological 
parameters with using population averages. Sensitivity in predicting local recurrence 
and predictive values were both better with individual parameters than with population 
averages. The accuracy of calculated probability of local control with the patient-
specific-parameter model reached borderline statistical significance (p = 0.07). 
In Paper III we investigated the entire material of head and neck carcinoma patients, 
including those receiving brachytherapy using a tumor control probability (TCP) model 
based on biologically effective dose (BED). Again we compared patient-specific 
radiobiological parameters with population averages to calculate individual TCPs. 
Evaluating the method using an ROC curve demonstrated a statistically significant 
difference in discriminating between local control or not when using patient specific 
parameters. This difference was not seen with population averages. 
In Paper IV, the role of a phosphine gold(I) compound in altering radioresistance in a 
radioresistant human lung cancer cell line U1810 was investigated. This effect is 
achieved by shifting the intracellular redox balance by inhibiting TrxR. After a single 
fraction of clinically relevant radiation doses, a clear radio-sensitizing effect on SF and 
repopulation was demonstrated. Gene expression analysis demonstrated genetic 
expression changes in related cellular pathways connected to DNA repair, cellular 
response to stress, and cell cycle.   
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1 INTRODUCTION 
 
Radiotherapy has been a successful way of treating cancer for the past 100 years. The 
development of different treatment schedules was driven by clinical experience 
regarding side effects of the delivered treatment. A major concern when treating a 
patient is the balance between getting enough dose to the tumor to eradicate all tumor 
cells but at the same time sparing enough normal tissue cells to preserve functions.  
 
1.1 CLINICAL RADIOTHERAPY 
 
Radiotherapy is used in several different cancers as a curative treatment option. It is 
used in carcinomas of different origins such as carcinoma of the head and neck, lung 
cancers and prostate carcinomas (1-4). Clearly, the surrounding tissues differ in 
structure and function, and knowledge of potential side effects after delivered treatment 
is essential. This is crucial in determining the total dose that may be delivered in the 
“target” representing tumor and areas with suspected tumor spread. 
 
The importance of inherent radiosensitivity was proposed by Fertil and Malaise in the 
early 1980s (5, 6). Tumor cells show a great difference in sensitivity to radiation. This 
is true for tumor cells of different origin but cancers with the same histology also show 
a wide range in their sensitivity to radiotherapy (7-10). Thus a sufficient dose to treat a 
certain type of cancer will be difficult to find as it varies between individuals with that 
cancer. Currant treatment schedules are adjusted to deliver a maximal dose based on 
previous experiences while avoiding long-term side effects in normal tissues in the vast 
majority of patients. This means that any given treatment results in a known risk of side 
effects (usually fewer than five per cent serious long-term complications) and a known 
chance of treatment success in a group of patients. However for an individual patient 
the dose to achieve treatment success is not known. A lower total radiation dose might 
be sufficient to eradicate all cancer cells with less risk of side effects in one patient as 
opposed to the entire patient population. Correspondingly in another patient there is no 
chance of a cure with the pre-specified radiotherapy dose but the same risk of side 
effects. 
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It would obviously be a great advantage for many patients if it was possible to predict 
outcome in terms of local tumor control after delivery of a specified radiation dose, or 
to predict the dose required for treatment success. Another valuable tool would be a 
means to sensitize tumor cells to ionizing radiotherapy while leaving normal tissue 
unaffected i.e. widening the therapeutic window for radiotherapy, balancing between 
treatment success and side effects.   
 
The radiosensitivity of tumor cells is controlled by different mechanisms. Inherent 
radiosensitivity refers to how well a cell can defend itself against radiation damage. 
Proliferation allows the tumor to grow between and during the treatment. Oxygen 
tension has a direct impact on radiation effect, with hypoxia and anoxia making the 
cells up to three times more resistant to ionizing radiation (11). Another factor of 
demonstrated clinical importance is the size of the tumor, with the trivial explanation 
that more tumor cells need more treatment (12). 
 
1.2 IONIZING RADIATION 
 
Radiotherapy consists of depositing ionizing radiation in pre-specified regions in the 
body. Radiation is mostly produced in and delivered by linear accelerators where 
electrons are accelerated by microwaves and either delivered for treatment or 
transformed into photons before hitting the target tissue. 
 
Ionizing radiation results in the ejection of electrons that in their turn damage molecules 
of different origins. This results in an ionizing cluster that when close to the DNA 
produces damage in the structure of the double helix that is difficult for the cell to 
handle. This can be expressed as double strand breaks (DSB) in the DNA molecule 
(13). The depletion into the cell of high energy that reacts with water consequently 
forms reactive oxygen species (ROS) (13, 14). The production of these free radicals 
that interact with oxygen and fixes damage to the DNA can be said to be the ultimate 
goal in radiotherapy. In addition to DSB, ionizing radiation results in single strand 
breaks (SSB). These, however are normally easier for the cell to repair as the unharmed 
strand of the DNA can serve as a template. A radiation dose of 1 Gy is believed to 
result in 20-40 DSB (15). Several defense mechanisms have developed to evade 
mutations with their possible detrimental consequences and consequently DNA damage 
to a cell can result in; repair, cell cycle arrest, senescence or cell death. 
   3 
 
1.2.1 Repair  
A delicate system of sensor proteins and enzymes is constantly checking the DNA for 
damage in order to initiate repair if needed (16). One repair pathway for DSB is 
homologous repair. This uses DNA from the opposite chromosome as a template for 
an exact repair (17). However, this is time-consuming and the cell needs to be in a 
cell cycle phase where the opposite DNA strand is available. Non-homologous end-
joining repair, using recombination, is faster but not exact and can result in mismatch 
repair, deletion or insertion; but allows the cell to survive (18). As an illustration 
ataxia telangiectasia mutated protein (ATM) is a part of the sensor system of DSBs 
together with several other proteins. ATM phosphorylates a protein, histone H2AX, 
which is then essential for recruiting other proteins necessary for DNA damage 
response (DDR) (19). Histones are important in packing the DNA and are proteins 
closely related to the DNA (20). Mutation of ATM as in ataxia telangiectasia 
normally results in enhanced radiosensitivity caused by the defect in detecting DSBs 
and consequently poor DDR. The MRN complex is another important protein 
complex taking part in sensing DNA damage together with ATM. It can interact 
directly with the damaged DNA and a dysfunctional or lacking MRN complex results 
in enhanced radiosensitivity in the same way as a defect in ATM does (18). 
Numerous proteins are consequently activated in response to radiation-induced DSBs 
and it is thought that ATM is the major protein transmitting these signals (21).  
 
1.2.2 Cell cycle arrest  
Activation of cell cycle checkpoints is an important part of DDR and delays the 
movement of cells through the G1, S and G2 phases (22). This gives the cell more 
time to initiate repair or decide whether the damage is so severe that it is inconsistent 
with survival. Inhibition of cyclin-dependent kinases (CDKs), proteins that make the 
cell move through the cell cycle, is essential for this to occur. This is controlled by 
phosphorylation or dephosphorylation depending on the CDK (23). As a result of this 
inhibition, transcription of genes essential for initiating DNA replication and 
movement through the cell cycle is stopped. ATM also plays a role in this process by 
inducing among others p53 or Chk 1/2 which play important roles in inhibiting these 
CDKs (24, 25).  
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1.2.3 Senescence  
Senescence signifies that the cell irreversibly stops to proliferate although it maintains 
its metabolic biological functions intact (26). A senescent cancer cell is no longer 
harmful as long as it does not start to proliferate again and it will eventually die for 
one reason or another. Severe damage to the DNA, especially DSBs, promotes 
damage-initiated senescence. This stress-induced senescence does not involve 
shortening of telomeres as in replicative senescence (27).  The induction of stress-
induced senescence is not fully understood but CDK inhibitors plays a role, and p53 
seems to be important in initiating senescence in response to ionizing radiation. As a 
result the cells enter a sort of permanent cell cycle arrest where chromatin changes 
and gene silencing might be present (28). 
 
1.2.4 Cell death  
Apoptosis is an active process characterized by specific morphological changes: 
programmed cell death. Enzymatic reactions result in DNA fragmentation, chromatin 
condensation and finally the cell breaks up into apoptotic bodies (29). Conditions inside 
the cell as well as external signals reflecting conditions outside the cell can initiate 
enzyme reactions and lead to apoptosis. Several enzymes are activated as a result of 
radiation and ultimately the balance of these enzymes controls the cell’s fate (30). If 
there is enough damage to the DNA the systems might act in favor of cell death instead 
of attempting repair. Activation of p53 by ATM results in induction of BAX, a pro-
apoptotic protein that causes release of cytochrome c from mitochondria. Consequently 
activation of a protease, caspase 9, leads to cleaving of cell target proteins. Apoptosis 
induced by caspase 9 in response to internal cellular damage is described as the 
intrinsic pathway (31).  
 
Autophagy is a well-controlled cellular process. It is initiated by the formation of 
autophagosomes containing different intracellular cytoplasmic constituents and their 
fusion with lysosomes resulting in degradation of the content (32). The process is 
activated by the inhibition of the mammalian target of rapamycin (mTOR) and can be 
initiated with rapamycin which inhibits mTOR (33, 34).  
 
Necrosis has been considered as an uncontrollable and accidental form of cell death 
caused by release of lysosomal degradative enzymes that attack the cell, leading to cell 
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lysis. Evidence, however, suggests that necrosis can be tightly regulated and follow  
oxidative stress and ROS generation in a cell (35). 
 
1.2.4.1 Mitotic cell death 
The major mechanism causing a clonogenic cell in a solid tumor to die after ionizing 
radiation is probably what is termed mitotic cell death (36). A tumor cell might 
continue to proliferate and go through several cell cycles after radiation before dying as 
a result of the radiation damage. Due to structural damage of the DNA resulting in 
mutation and chromosomal aberrations, the cell has lost its clonogenic ability. This loss 
is the result of repair processes that are unfaithful to the genetic information and 
consequently not functional or in agreement with cell survival. The final process, 
mitotic catastrophe, is caused by the incapacity of the cell to complete mitosis 
successfully (37). The cell may subsequently die from various forms of programmed 
cell death such as apoptosis, autophagy or necrosis (38). 
 
1.2.4.2 Surviving fraction after ionizing radiation 
The surviving fraction after ionizing radiation can be expressed as the fraction of 
clonogenic cells surviving a radiation dose. There is a random nature in cell survival 
after radiotherapy. In brief, a hundred lethal lesions distributed randomly to a hundred 
sensitive cells will not kill all cells. Some will get more than one lethal hit but cannot 
become “more dead” as a result, while others get no hit at all and will consequently 
survive (39). As a fraction of cells will survive after radiation their number is directly 
related to the initial number of cells (12). This emphasizes the importance of tumor size 
for tumor cell survival after radiotherapy. While tumor size does affect outcome after 
radiotherapy, it is not alone as good an indicator of treatment outcome as might be 
expected (40, 41). The survival of cells after radiotherapy is, in addition, affected by 
factors such as DNA damage-response mechanisms, scavenging of free radicals and the 
cell environment i.e. oxygen tension. These factors differ between tumors and affect 
cellular radiosensitivity. 
 
1.3 FRACTIONATED RADIOTHERAPY 
 
A course of radiotherapy is as a rule delivered as a number of smaller fractions. This is 
done primarily to spare the normal tissues as much as possible from side effects: the 
basis for this will be presented later. However, this practice was developed empirically 
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when radiotherapy was first introduced as a treatment modality and it was soon 
discovered that fractionation gave an advantageous balance between treatment effect in 
the tumor and side effects in normal tissue (42). Cell survival after fractionated 
radiotherapy is affected by the four “Rs” of dose fractionation as introduced by 
Withers: repair of sublethal damage, repopulation, redistribution through the cell 
division cycle and reoxygenation (43). A fifth factor, inherent radiosensitivity, has been 
proposed as an explanation of different tolerance to fractionated radiation in different 
tissues (44).  
 
1.3.1 Repair and redistribution 
The ability to detect damage to DNA is essential for normal cell development and cell 
survival. As DNA double-strand breaks are thought to be the major cause of cell 
sensitivity to radiation the number of unrepaired DSB after radiotherapy correlates with 
cell survival (45). The capacity to repair damage to the DNA thus affects 
radiosensitivity and varies between cells. This is evident in patients with mutation in 
repair enzymes such as the ATM protein as described above, which results in an 
extraordinary radiosensitivity with a high fraction of cell kill due to impaired detection 
of DNA damage and repair. The response to damage is crucial for whether the cell is to 
continue to cycle and proliferate, or die. The “quality” of repair is also important in the 
context that DNA must be functional after repair or the ability of the cell to continue to 
divide is lost and it will eventually die. This highlights the importance of cellular 
systems both detecting damage and then initiating a repair that is correct. The balance 
in these systems is also important. The detection of DSB by ATM can initiate repair 
mechanisms but also the activation of the tumor suppressor gene p53 (46). The p53 
protein plays an important role in controlling cycle arrest and also acts as a 
proapoptotic enzyme that by stimulating caspase activity leads to cell death by 
apoptosis (24, 31). The repair of DSB in the DNA is either by homologous repair where 
the corresponding unharmed DNA on the other sister chromosome is used as a 
template for the damaged base pairs, resulting in a perfect repair. The alternative is 
non-homologous end joining repair in which the DNA strings are mended disregarding 
missing base pairs in the process (47). As a consequence genetic information might be 
lost or risk misinterpretation (48). Repair of the DNA that is not functional (or if there 
is no repair), such as certain rearrangements or DNA breaks, can lead to mitotic 
catastrophe which in turn leads to cell death (see mitotic cell death above). 
 
   7 
Progression through the cell cycle is also important when considering radiosensitivity. 
Cells show great difference in radiosensitivity in different cell-cycle phases, being 
sensitive in G2-M and resistant in late S-phase (49). One possible explanation of this 
resistance in the S-phase is that the other chromosome is opened and readily accessible 
for homologous repair of DSB. After being irradiated, surviving cells are in general in 
more radioresistant cell-cycle phases and radiosensitivity depends on how the cells 
progress to more sensitive phases. As mentioned above inhibition of CDKs after 
radiotherapy is important for the cell to stop cycling and consequently remain in these 
radioresistant phases (24). The potential impact on radiosensitivity of cell-cycle arrest 
in more resistant cell-cycle phases after radiation can be hypothesized (50). 
 
1.3.2 Proliferation  
Tumor cells divide and proliferate in an uncontrolled manner. When most apparent, 
tumor growth can be observed in the clinic during a course of radiotherapy (51). The 
consequence for the patient is obviously severe, with symptoms of tumor progression in 
addition to side effects of the treatment. This is fortunately uncommon, although 
continued proliferation during radiotherapy is a clinical problem (52-54). A protracted 
treatment requires an increased total radiation dose for the same chance of local control 
as with the original treatment schedule. Withers et al. have proposed a model where an 
accelerated proliferation kicks in after a lag period of about four weeks without 
clinically significant tumor growth (54). However, the basis for this assumption has 
been questioned. Dubben has in the same material shown a lack of a dose-response 
relationship between tumor control rate and normalized total dose in 2 Gy fractions 
(55). This indicates that the time effect observed could be related to an equivalent 
radiation dose i.e. longer treatment schedules deliver higher radiation doses. Bentzen et 
al. drew yet other conclusions, again studying the same material. They assumed a much 
shorter lag period, if any, before onset of proliferation or alternatively continuous 
tumor-cell proliferation with a cell-doubling time of little less than a week (56). Even 
so, in most relevant clinical radiation schedules proliferation must be accounted for. In 
the majority of recent papers a delay of three weeks after beginning radiotherapy is 
often applied before repopulation is considered to begin (57). This limit can be viewed 
as arbitrary since even if there is a lag period with no proliferation this will probably 
vary considerably between individuals. The question whether there is a lag period after 
initiation of radiotherapy before repopulation begins at a certain rate or whether 
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proliferation at a lower rate exists throughout treatment has, moreover, not been 
answered.  
 
Tumor proliferation can be measured in many ways. Tpot describes the potential 
doubling time in a tumor with no cell loss during tumor growth (58). Cell loss during 
tumor growth is normally caused by diverse factors such as lack of nutrition or oxygen. 
In clinical materials Tpot has not been proved sufficiently robust to demonstrate a 
relationship between tumor proliferation and local control after radiotherapy. However, 
a feasible relationship between highly proliferative tumors expressing an elevated 
labeling index (LI) and impaired local control has been shown (59). The labeling index 
represents the mitotic activity in a tissue representing cells in S-phase in relation to the 
total number of cells (60). Nevertheless Tpot has been considered a better predictor of 
tumor regeneration than measured tumor growth before radiation. Assuming that cell 
kill during a course of radiotherapy is caused mainly by radiation damage, and not 
hypoxia or lack of nutrition, it can be thought that tumor cell repopulation moves 
towards Tpot. However it has also been suggested that tumors as well as normal tissue 
can sense damage and initiate accelerated proliferation as a response to this (61).The 
importance of proliferation is further demonstrated by the potentiating effect of 
chemotherapy concomitant with radiotherapy. This additive effect can at least partly be 
attributed to slower proliferation due to the cytotoxic drug (62).  
 
1.3.3 Hypoxia 
Hypoxic cells are more radioresistant than well-oxygenated cells. This has been 
demonstrated in vitro by irradiating tumor cells during both well-oxygenated and 
hypoxic conditions (63, 64). Ionizing radiation readily reacts with intracellular water 
and in the presence of oxygen creates hydroxyl radicals that in turn damage the DNA 
and are also able to fixate DNA damage (14, 65). During hypoxic conditions this 
damage is more likely to be repaired instead. Hydroxyl radicals also react with other 
molecules in the cell. All these created free radical species have longer half-lives during 
hypoxic conditions and can react with hydrogen as an alternative to oxygen to restore 
their structure and form water molecules instead of secondary peroxy radicals (60). 
Hypoxia in tumors before radiotherapy correlates with a worse prognosis (66, 67). 
However hypoxia in tumors before surgery has also demonstrated similar results, 
correlating with poorer prognosis (68). From these results it is clear that hypoxia itself 
is a bad prognostic factor and has also been related to the tumor’s metastatic capacity.  
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The reason for this might be selection of tumor cells that support hypoxic conditions 
better and become resistant to hypoxia-induced apoptosis, for example by mutation of 
p53 (69). The cells adapt to the hypoxic condition and can stimulate angioneogenesis. 
Hypoxia has also been claimed to change DNA repair towards a more pronounced 
malignancy grade with suppressed expression of several DNA repair genes resulting in 
genomic instability (70).  
 
The effect of radiation thus depends on the oxygen tension in the tumor. The oxygen 
enhancement ratio is the factor by which tumors respond better to radiation in oxic than 
hypoxic environments. This ratio has traditionally been set to between two and three 
(71). However most experiments have been performed with large radiation doses and 
the enhancement ratio is probably less significant in the dose range used in the clinic 
for most fractionated regimens (72, 73). In hypofractionated treatment regimens there 
could theoretically be a significant clinical problem due to the larger radiation doses 
usually delivered. Experience of stereotactic radiotherapy has nonetheless shown very 
promising results not indicating a serious problem potentially caused by hypoxia (74, 
75). The use of a hypoxic radiosensitizer in combination with primary radiotherapy for 
carcinoma of the head and neck has, however, showed improved loco-regional control 
indicating an hypoxic effect in conventional radiotherapy treatment situations (76). 
Reoxygenation is a continuous process in tumors during fractionated radiotherapy. This 
is to some extent due to tumor shrinkage getting the remaining tumor cells closer to 
intra tumoral blood vessels. These blood vessels are, however, often of poorer quality 
resulting at times in impaired blood perfusion and thereby causing acute hypoxia in 
tumors (77). The nature of temporary hypoxia in tumors has been demonstrated in 
several studies (78-80), indicating that most tumor cells are oxic at least in periods 
during a course of radiotherapy. The clinical impact of hypoxia on tumors during 
fractionated radiotherapy is therefore difficult to assess, and oxygenation will most 
likely vary during radiotherapy in most tumor cells. It is clear that hypoxia influences 
radiosensitivity but the effect of reoxygenation most likely reduces this effect in 
fractionated radiotherapy and the net effect might be fairly limited (81).  
 
1.4 OXIDATION REDUCTION (REDOX) SIGNALING 
 
Interaction between cellular proteins and DNA is an important mechanism in the cell, 
controlling functions such as transcription, repair and replication (82). This interaction 
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regulates gene expression, which in turn controls cell metabolism including cell growth 
and cell survival. The possibility of interaction between a protein and its target, for 
example the DNA binding site, depends on the protein structure and its three-
dimensional shape (83). This is controlled by post-translational mechanisms such as 
phosphorylation and methylation. In addition oxidation reduction (redox) of proteins 
plays a major role in controlling protein function (84). Redox-regulated proteins can 
sense changes in the oxidation-reduction balance in different ways; one common one 
being through a reactive cystein residue with a thiol-coordinated zinc site within the 
protein (85). The agent responsible for the changes in redox balance is reactive oxygen 
species (ROS), produced both within and outside the cell. As these ROS can be 
hazardous for the cell in high concentrations - although essential for cellular 
metabolism at physiological levels - the cell has systems for both production and 
elimination of ROS (86).  
 
1.4.1 Thioredoxin-thioredoxin reductase 
Thioredoxin (Trx), a small protein, contains a dithiol group which is reduced from 
disulfide in the oxidized state by thioredoxin reductase (TrxR), another small 
selenoprotein (87, 88). Trx has several important biological functions in its reduced 
state. Transcription factors such as p53 and activator protein 1 (AP-1) interact with Trx 
in the nucleus to enable their interaction with DNA (89). A binding between reduced 
Trx and apoptosis-signal-regulating kinase 1 (ASK-1) prevents downward signaling for 
apoptosis (90). Another important function is as an antioxidant keeping the intracellular 
environment reduced by acting as a scavenger for ROS. Trx is a hydrogen donor to 
ribonucleotide reductase, which highlights its importance in the construction of new 
DNA and involvement in repair processes. TrxR reduces oxidized Trx in a NADPH-
dependent process and is therefore essential for a functional Trx - TrxR system (87). 
Several gold compounds such as auranofin, a clinically used anti-rheumatic drug, are 
both selective and effective inhibitors of TrxR and consequently also Trx (91, 92). 
 
1.4.2 Thioredoxin and radiation 
Activation of intracellular thiols such as glutathione and Trx by oxidative stress and 
irradiation affects radiosensitivity (93, 94). Trx is over-expressed in several types of 
cancers (95), and low levels of ROS have been demonstrated in cancer stem cells and 
correlate with increased resistance to radiation (96). One relevant function in response 
to ionizing radiation is to act as a scavenger and reduce oxidized molecules (97) that 
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otherwise might interact with and damage DNA by causing and fixating strand breaks. 
Oxidative stress which leads to depletion of reduced Trx can result in apoptosis 
triggered by the higher levels of free ASK-1 then unbound by Trx. Depleted levels of 
cellular thiols have been associated with increased radiation-induced apoptosis (98) 
while increased levels of Trx have been associated with increased radioresistance in a 
malignancy-induced human cell line (99).  As mentioned above, Trx plays a role in 
stimulating the DNA-binding activity of several transcription factors important in 
conditions of cellular stress. A role has also been demonstrated for Trx in reducing and 
thereby activating the Ape1/Ref1 complex that plays a central role in base excision 
repair (100, 101). Finally, Trx acts as a hydrogen donor to ribonucleotide reductase, 
emphasizing its role in DNA construction and repair (87).  
 
1.5 MODELING IN RADIATION 
 
In contrast to great improvements of the technical aspects of delivering radiotherapy 
during the past ten years, no improvement in biological optimization has been achieved. 
Modeling radiotherapy would be a helpful tool in tailoring individual treatment or 
deciding whether a person would benefit from a prescribed treatment schedule (102). 
However, no mathematical model to predict treatment outcome after radiotherapy has 
been validated so far. For this, several obstacles remain. First what radiobiological 
parameters are required in a mathematical model has to be verified. Inherent 
radiosensitivity, tumor-cell proliferation and tumor oxygen tension are considered to be 
the most important parameters and are therefore the most studied. Inherent 
radiosensitivity measured as surviving fraction after 2 Gy (SF2) correlates with local 
control after radiotherapy (103, 104). On the other hand measurements of proliferation 
using Tpot have demonstrated conflicting results and have not been shown to correlate 
with clinical outcome; nor have other parameters that measure proliferation come into 
clinical use (59). A factor in the tumor micromilieu, oxygen tension specifically affects 
clinical outcome when measured before treatment (67). However, this factor also varies 
considerably during a course of radiotherapy (105-107). Gene expression analysis 
might offer yet other ways to consider radiosensitivity (108) as well as analysis of DNA 
end-binding complex density (109), although no recent papers on these subjects 
showing clinically applicable results have been presented (110).  
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Numerous models have been presented over the years in attempts to predict clinical 
outcome after radiotherapy (111-113). The maybe most widespread model, the LQ 
formula, is a mathematical adaptation to fit cell-survival curves after radiation with 
different doses and fractionations. This model has been adapted in many ways (102). 
The radiobiological parameters used in such models are normally population averages 
derived from interpreting local control data from clinical studies. In other words the 
radiobiological tumor characteristics assumed are based on tumor control data and 
fitted to the different parameters used in the specific model. The usefulness of any of 
these models in the clinic to guide what treatment schedule to use in an individual 
patient seems very distant, even though some guidance on the population level in 
developing radiation schedules for a certain tumor type might be appropriate. 
A predictive model that considers individually measured radiobiological data is 
therefore warranted. This would probably consider several of the radiobiological 
parameters mentioned above. One factor that has to be considered is the reliability of 
such measurements in vivo. Still, this has to be evaluated in prospective clinical trials. 
Another and equally important issue is the feasibility of such measurements and further 
development of easy, and fast methods to acquire individual tumor-specific 
radiobiological information is essential. Despite these initial remarks mathematical 
models are in wide clinical use in modern radiotherapy. They have important roles in 
comparing different dose schedules and in deciding continued treatment after an 
unexpected treatment pause, to name a few examples. However a prospective model to 
decide the best treatment schedule for an individual patient is yet to be developed (114).  
 
1.5.1 A radiobiology model 
For many physicians a model based on radiobiological parameters reflecting actual 
tumor-biological features would be a simple and intuitive way to predict radiotherapy 
outcome. These thoughts were the basis for the following model predicting outcome in 
the form of surviving cells after fractionated radiotherapy as presented by Brodin (115):  
 
        
       
 
Number of surviving cells after N fractions (CN) is related to the initial number of 
tumor cells (C0) by surviving fraction (SF) and proliferation (P): 
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The doubling time of the cell population (Td) in relation to the time between fractions 
(t) subtracting the mitotic delay (m) affects the proliferation factor. This model is easy 
to understand, and the number of surviving cells is an endpoint that is very easy to 
relate to in terms of achieving local control or not. The number of tumor cells in a 
tumor is thought to be related to its size and therefore easy to appreciate (60). 
 
1.5.2 The multi-target model 
The multi-target model describes an initial slope of the survival curve (D1) caused by 
single-hit cell kill, and a final slope (D0) due to multiple-event cell killing. In this model 
an extrapolation number (n) represents the number of sensitive targets in a cell. This 
model previously dominated in describing cell survival curves after radiotherapy. D0 
represents the dose that reduces cell survival from 1 to 0.37 (or e
-1
), and this term is still 
widely used to describe a radiation dose that reduces cell survival by one natural 
logarithm. The explanation of this is a dose that delivers an average of one lethal hit per 
target. This model is not the most used today, maybe because of the difficulty to define 
what the radiation target actually consists of and the more complex equation compared 
to the LQ model. However it still represents a good fit to expected cell survival after 
radiotherapy, especially in very radiosensitive tumors and tissues. 
 
1.5.3 The LQ model 
The most commonly used model to describe the shape of the cell survival curve today 
is the linear-quadratic (LQ) model: 
 
              
           
   
 
Cell survival (S) is related to dose with a factor α that expresses a linear relationship 
with dose and a factor β that is related to the square of the delivered dose. The result is 
a continuously bending response to radiation dose which has proved very useful to 
describe response in the clinical relevant dose range (0.5 – 6 Gy). The shape of the 
curve is described by α/β, where a higher rate gives a more linear curve and a lower a 
“curvier”. The model is mathematical to fit the experienced cell survival after radiation 
(116). However, biological explanations have been proposed. Curtis introduced the idea 
where the linear α component is due to single-hit lethal lesions and the quadratic β 
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component depend on repair of sublethal damage that can accumulate to lethal damage 
(117). Saturation deficit of repair enzymes at high dose ranges is another possible 
explanation (118). At low radiation doses the α effect dominates and is of major 
importance when delivering clinically relevant doses of around 2 Gy in fractionated 
radiotherapy. 
 
Figure 1. Cell survival curve demonstrating contribution of the linear α-component and quadratic β-
component to the combined cell survival curve. α/β represents the dose where the components 
contribute equally to cell kill. 
 
 
Differences in α/β 
The α/β value represents the dose where the linear contribution to cell kill expressed as 
α equals the quadratic contribution expressed as β (Figure 1). Differences in α/β express 
differences in the tumor or tissue response to fractionated radiotherapy (119). A low 
α/β signifies less tissue damage if the radiation dose is delivered in several smaller 
fractions whereas this difference is less pronounced in tissues or tumors with a high α/β 
value. This is an advantage in clinical radiotherapy where fractionated radiation spares 
normal tissue around a tumor more than the tumor itself i.e. a favorable therapeutic 
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ratio. Several studies have defined the value of α/β in different tissues and in tumors. In 
general late-reacting tissues have a lower α/β value, in the clinic often set to 3. Highly 
proliferative, acutely reacting tissues on the other hand have a high α/β of at least 10, 
which is the most common value applied when performing calculations in a clinical 
setting (116). Tumors are considered to have α/β values similar to acutely reacting 
tissues: however, a wide range has been demonstrated probably due to wide differences 
in tumor biology (120). Exceptions are prostate cancer with an α/β of around 3 or even 
less (121), while data supports the assumption that carcinoma of the breast has an α/β 
somewhere between 3 and 10 (122).  
 
1.5.4 Isoeffective dose in fractionated radiotherapy 
It has proved very useful to have a model in clinical practice to compare radiation effect 
in acute and late-reacting tissues when using different fraction sizes and total dose. This 
difference and possible applications with optimization of dose per fraction was 
introduced by Thames et al in 1982 (119). A simple isoeffect equation was proposed by 
Withers in 1983: 
 
  
  
 
        
        
 
 
where (D) is total radiation dose in the different treatments schedules, (d) is the dose 
per fraction and (α/β) defines the reaction of the tissue to radiation (late- versus early- 
reacting tissue or tumor) (123). 
 
1.5.5 Biological Effective Dose (BED) 
BED is the theoretical total dose to achieve an isoeffective dose in a tissue or tumor 
using infinitely small doses per fraction and infinitely numerous fractions (124). It 
demonstrates the relationship between the total dose, dose per fraction and tissue 
response to radiation: 
 
                 
 
where (D) is the total radiation dose, (d) the dose per fraction and (α/β) defines the 
shape of the cell surviving curve to ionizing radiation as described above. The addition 
of a time factor completes the BED formula: 
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where (n) is the number of fractions delivered in (T) total time, (Tp) is the cell doubling 
time and proliferation start at the time (Tk) (k of kick-off). The clinical use of this 
equation is evident in comparing the effect of a radiotherapy schedule for tissues with 
different α/β, or estimating what a change in dose per fraction would result in. The 
minus sign before the time factor emphasizes the disadvantageous effect of prolonging 
a treatment schedule (if T is larger than Tk), reducing the biologically effective dose 
according to this model (125). For biologically equivalent doses divide the BED by a 
factor in relation to dose and α/β. For equivalent doses in 2 Gy divide BED by 1.67 for 
an α/β of 3 (late responding tissues) and by 1.2 for an α/β of 10 (tumors and acutely 
responding tissues). This is explained by this part of the equation:          . 
 
1.5.6 TCP according to the Poisson model 
The probability of tumor control depends on the number of surviving tumor cells, 
clonogens, which sustain the ability to proliferate after radiotherapy (126). This is 
useful when considering a group of patients with tumors receiving radiotherapy. The 
basis is the random nature of cell killing resulting in different numbers of surviving 
clonogens in the different tumors, from zero (cure) and upward (no cure). Cell survival 
in a tumor will follow a Poisson distribution after a specified radiation dose i.e. a 
sigmoid curve (12). The median number of surviving clonogenic tumor cells gives the 
tumor control probability:  
 
           
 
where (N) is the number of clonogenic cells before radiation and (SF) is the surviving 
fraction of cells after radiation. TCP curves for human tumor control are in general 
shallow even if tumor size is considered, indicating tumor heterogeneity in sensitivity 
to radiotherapy (127).   
 
1.6 BRACHYTHERAPY 
 
No details of brachytherapy are provided here; only a brief summary is presented. 
Brachytherpy involves bringing the source of radiation close to the target and using 
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radiation with a very short range. This permits the delivery of high radiation doses 
while at the same time sparing surrounding normal tissue. Doses can be delivered in a 
shorter or a longer time frame. When delivered as low dose rate, i.e. during a longer 
time, continuous repair can take place and the tumor survival curve is defined mainly 
by α. Therefore when considering brachytherapy delivered at lower dose rates in a 
mathematical model the continuous repair has to be accounted for. 
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2 AIMS OF THE STUDY 
 
2.1 OVERALL AIM 
 
The overall aim of the work presented in the present thesis was to increase 
understanding of the predictive capacity of the individually measured radiobiological 
parameters inherent radiosensitivity, proliferation and number of tumor cells on 
treatment outcome after radiotherapy. How changing the cellular redox balance affects 
inherent radiosensitivity and repopulation after ionizing radiation was also investigated. 
 
2.1.1 Specific aims 
Specific aims were 
 
- to evaluate the usefulness of two radiobiological models based on inherent 
radiosensitivity, proliferation and the number of tumor cells to predict outcome after 
radiation, 
 
- to establish whether individually measured radiobiological parameters are better in 
predicting clinical outcome than average population based parameters, and 
 
- to investigate the possibility of affecting inherent radiosensitivity by altering the redox 
status in tumor cells using a gold compound, and the corresponding affect on gene 
expression. 
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3 MATERIAL AND METHODS 
 
3.1 MATERIAL 
 
Established lung cancer cell lines were used in papers I and IV and previously 
published data originating from patients treated for head and neck carcinomas at 
Sahlgrenska University Hospital were used in papers II and III. 
 
3.1.1 Cell lines 
Five well-characterized human lung cancer cell lines were used in paper I: three small 
cell lung cancer cell lines; U-1285, U-1906E, U-1906L, one squamous cell carcinoma 
cell line U-1752 and one large cell carcinoma cell line U-1810 (128, 129). All had well-
defined radiobiological characteristics. In paper IV, U-1810 was used due to its known 
radioresistant features and U-1906L was used as a radiosensitive control. 
 
3.1.2 Patient-related data 
Previously published data originating from patients treated for carcinoma of the head 
and neck at the Oncology Department at Sahlgrenska University Hospital in 
Gothenburg was used (130). Tumor material had been collected from numerous 
patients and tumor biological characteristics had been investigated. In studies II and III 
we used data where all the following parameters were known; inherent radiosensitivity 
expressed as SF2, tumor proliferation (Tpot), tumor size, external radiation dose and 
duration of treatment. In study III information regarding brachytherapy i.e. dose-rate 
and duration, was also used. 
 
3.2 METHODS 
 
3.2.1 Radiosensitivity assays 
Clonogenic assay (paper I) 
The clonogenic assay is considered the “gold standard” for characterizing inherent 
radiosensitivity. A cell suspension is prepared and plated in a cell culture medium 
(131). The cell cultures are then irradiated or kept as control and incubated for a period 
of time. The ability to form viable colonies is then investigated. The numbers of 
colonies formed, in treated versus untreated plates, are compared and the difference 
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will represent the surviving fraction. In this study cells were suspended on agarose 
mixed cell-culture medium. 
 
Extrapolation method (papers I and IV) 
An extrapolation method has been proposed as an alternative in cell cultures with low 
clonogenic capacities and consequently are unsuited for the clonogenic assay (132). 
The extrapolation method explores the cells ability to proliferate after treatment. The 
cells, treated or untreated, are kept in cell culture medium for a period of time after 
treatment. They are sub-cultivated and the medium changed repeatedly to keep culture 
conditions optimal and cells are counted at the same time. The number of cells on each 
occasion (corrected for the dilution factor) is plotted on a logarithmic scale and is 
finally extrapolated back to the intersection with the y-axis, representing number of 
cells at the time of treatment. The difference between treated and untreated cell cultures 
represents the “surviving fraction” (Figure 2). For the method to be successful, the 
irradiated cells must proliferate at the same rate as the control in the exponential growth 
phase and all cell loss must be attributable to the radiation. 
 
3.2.2 Radiation 
Radiation was performed using a linear accelerator, a cobalt machine or a Gamacell 
Exactor. 
 
Linear accelerator (paper I) 
A linear accelerator produces photon radiation by accelerating electrons and then 
causing them to halt abruptly. A bolus is used to get a sufficient dose superficially in a 
tissue or, as in the present studies, in the cell suspension. We used 8 or 16 MeV with a 
dose rate of 4 Gy/min. Changing the duration of radiation results in different total 
radiation doses. 
 
Gamacell exactor (paper I) 
We used a Gamacell 40 Exactor where the radiation was produced by a Cs
137
 source. 
The dose rate was 1.29 Gy/min in the dose range 0-1 Gy and 1.23 Gy/min for 2 Gy and 
above. Varying the duration of radiation results in different radiation doses. 
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Figure 2. The growth curve of a cell line after irradiation and the corresponding 
extrapolation from the exponential part of the curve. 
 
 
 
 
Cobalt-60 machine (paper IV) 
Cell lines were irradiated with a machine using an ionizing Cobalt source with a dose 
rate of 0.50 – 0.51 Gy/min. The duration of radiation affects the delivered dose. 
 
3.2.3 Laboratory work in paper IV 
Inhibition of TrxR 
A gold compound [Au(SCN)(PEt3)] was used and cell lines were incubated with 2.5 
µM of the compound 24 hours prior to treatment and kept for 24 hours after treatment.  
siRNA are short double-strand RNAs able to prohibit the expression of a gene and 
consequently the corresponding gene product or protein. Suppression of TrxR1 as 
described in this paper was achieved by reverse transfection using 10 nm TXNRD1 
Silencer
®
 Pre-designed siRNA, ID:111302 and Silencer
®
 Negative Control siRNA #1 
(Ambion). The transfection reagent used was siPORT
TM
 NeoFX
TM
 (Ambion).  
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Measurements of TrxR 
The amount of active TrxR was established with insulin as a substrate (133). The 
activity of reduced Trx is measured by its ability to reduce protein disulfides in insulin. 
An excess of Trx is added and the Trx-dependent formation of SH groups in insulin is 
determined by comparison to a standard curve with known concentrations of human 
TrxR measured by absorbance at 412 nm. 
 
Real-time qPCR 
Reversed transcriptase produces cDNA from mRNA for subsequent use in the PCR. In 
paper IV SYBR green was used to detect double-stranded DNA during the 
amplification process. SYBR green binds non-specifically to double-stranded DNA and 
then emits green light (fluorescence), permitting quantification of amplified DNA. The 
number of cycles needed to achieve a specified fluorescence threshold is directly 
related to the amount of nucleic acid originally present in the sample. This is because 
the more nucleic acid copies originally put in the original sample the fewer cycles are 
needed to reach the threshold. 
 
Western Blot 
The Western blot method detects protein in cell extracts using protein-specific 
antibodies. Western blot was used in paper IV to detect TrxR. First proteins are 
separated according to size using gel electrophoresis. After being transferred to a filter, 
antibodies against the protein of interest are probed. Finally a secondary antibody is 
added, in this case a HRP-conjugated antibody that is detected using 
chemiluminescence. 
 
Cell cycle analysis 
Flow cytometry is used to identify cells in different phases of the cell cycle. This is a 
method where cells pass a beam of light, usually laser, and detectors pick up scattered 
and fluorescent light reflecting both cell volume and cell content. To perform cell-cycle 
analysis the cells are made permeable and treated with a fluorescent dye, in paper IV 
propidium iodide. This stains DNA quantitatively and consequently the fluorescence 
intensity will correlate to the DNA amount in the cell, which in turn reflects the 
different phases of the cell cycle. 
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RNA isolation 
For RNA isolation, cell solutions are lysed in the presence of a buffer that inactivates 
RNases. The total amount of RNA containing 200 bases or more will then bind to a 
silica-gel-based membrane and this selectivity enriches the mRNA content since 
shorter forms of RNA are excluded. 
 
Gene expression profiling 
The microarray technique employs a large set of oligonucleotide probes attached to a 
surface, for instance a silicon chip. A sample containing nucleic acid is subsequently 
added which results in hybridization between the probe and sample nucleic acid, for 
example mRNA (cDNA). Non-specific bonds are washed off. The amount of target-
sample binding will be reflected by fluorescence. This allows a gene expression 
analysis of the sample to be made. Due to the large amount of data produced by 
microarrays it is important to manage it in a correct way. Background noise has to be 
accounted for and the data is normalized to minimize statistical errors. In study IV the 
Affymetrix GeneChip scanner (Santa Clara, Ca, USA) was used to measure changes in 
gene expression in cell lines U-1810 and 1906L after radiation and exposure to the gold 
compound[Au(SCN)(PEt3)]. The data so produced was processed with an Affymetrix 
expression console. 
 
3.2.4 Radiobiological models 
In papers I and II a model including inherent radiosensitivity, proliferation and tumor 
size was used, see radiobiology model above:  
 
        
       
 
where CN is the number of cells after N irradiation treatments, C0 equals the original 
number of cells immediately before first treatment, SF is the surviving fraction of cells 
for each dose and cell line and P is the proliferation factor describing exponential 
growth:  
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where t is the time interval between fractions, m is the mitotic delay set to 1.5 h/Gy and 
Td is the doubling time of the cell population. This might imply the potential doubling 
time if all cell kill is afforded by irradiation. 
 
In study II the Poisson model was used to calculate tumor control probability (TCP) 
after radiotherapy according to the following equation: 
 
         
 
In study III the biologically effective dose (BED) was calculated using the following 
equation for external beam radiotherapy: 
 
 
 
 
where n is the number of fractions, d the dose per fraction and α/β defines the shape of 
the cell surviving curve. For Brachytherapy the following equation was used to 
calculate BED: 
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where D is the total radiation dose, T is the total treatment time and µ represents the 
repair coefficient of sub-lethal damage during brachytherapy. 
 
Most patients received combined therapy and the total BED was calculated after 
possible proliferation had been subtracted according to the following equation: 
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LQ model. Note that no correction for proliferation is needed if the overall treatment 
time is shorter than Tk. 
 
In study III the Poisson-LQ model was used to calculate the TCP according to the 
following equation: 
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where N0 is the initial number of clonogenic cells in the tumor. The EQD2 is the 
equivalent dose in 2 Gy per fraction of the total biological effective dose received by 
the patient and calculated as follows: 
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3.2.5 Statistical methods 
The following well-established statistical methods were applied accordingly: Student’s 
t test, the Chi-square test, the Mann-Whitney U test and Wilcoxon’s matched pairs test. 
They are referred to in THE respective paper. Statistical analysis of microarray data 
were analyzed according to protocol using Student’s t test for gene expression levels 
and Pearson correlation for relationship between each treatment category and are 
presented in study IV.  
 
Receiver operating characteristic (ROC) analysis was used in study III. ROC curves 
may be used to present the sensitivity of the test versus its false-positive rate. ROC 
analysis determines how well a system (or method) can answer a question and 
distinguish a difference in a studied object or population (134, 135). The area under 
the curve represents the accuracy of the test, the greater the area the better the result. 
In general, a straight line where the area under the curve equals 0.5 represents a 
worthless test and an area over 0.9 an excellent test. Comparing two methods, the 
method with a better true positive fraction for the same true negative would be 
considered better. An optimal test and cutoff value with 100% sensitivity and 100% 
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specificity would thus be plotted in the upper left corner (sensitivity = 1 and 1-
specificity = 0) (Figure 3). 
 
Figure 3. Examples of ROC curves, for details see text. 
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4 RESULTS AND DISCUSSION 
 
4.1 STUDY I 
 
The usefulness of radiobiological parameters in predicting clinical outcome after 
radiotherapy has not been fully clarified. Study I sought to evaluate a radiobiological 
model by comparing predicted and experimentally found effects of incorporating 
proliferation with inherent radiosensitivity in five tumor cell lines to see whether this 
resulted in better accuracy in predicting radiation responsiveness.  
 
Radiosensitivity after fractionated radiation differed in the five investigated human 
tumor cell lines, the most sensitive cell line showing a greater response to fractionated 
radiation than the more radioresistant cell lines. The latter were comparatively more 
sensitive to hypofractionation. In the three cell lines where SF was evaluated with the 
clonogenic assay, adding proliferation to single-dose SF seemed to get a prediction of 
SF after fractionated radiation that came closer to the experimentally achieved 
“fractionated” SF. This was not seen in the two cell lines where SF was measured with 
the extrapolation method. Interestingly in these two cell lines, prediction of SF and the 
experimentally measured SF after fractionated radiation were very similar in each 
fractionation regime whether proliferation was added to single dose SF or not. The 
methodology of the extrapolation method permitted establishment of the observed 
doubling time of the two cell lines. This clearly showed that proliferation took place 
during and after fractionated radiation: it even accelerated as the measured doubling 
time was reduced after the first two weeks. Our conclusion is that the extrapolation 
method was not useful in this experiment. There might be several reasons for this. As 
mentioned above cell kill must be caused by the irradiation for the method to be 
reliable. In this experiment with repeated radiation sessions and frequent sub-
cultivations this might not be the case. This may also have affected the cell doubling 
time after radiation. We did observe a difference in the changes of the cell doubling 
time after radiation in the two cell lines compared to control. This implies that the 
proliferation rate in the exponential part of the cell growth curve may have differed 
between cell lines and control, making the experiment difficult to interpret.  
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The extrapolation method and clonogenic assay have previously been compared in 
achieving SF after a single dose of radiation. No major difference was found (128). It 
might be hypothesized that the risk of introducing other causes of cell loss and the 
proliferation effect is minor in relation to a single fraction; but when multiplied as is the 
case in fractionated treatment schedules, the effect gets more pronounced. This model 
for predicting radiosensitivity after fractionated radiation using the number of tumor 
cells and earlier established SF, and including Tpot, seemed to give a better prediction 
in three cell lines than the exclusion of proliferation did. In two of the cell lines the 
effect of proliferation was difficult to evaluate. No lag time before onset of proliferation 
after first radiation was observed in these cell lines. These results suggest that it is 
important to include proliferation in calculation of SF after fractionated radiation when 
using the clonogenic assay to establish SF.  
 
4.2 STUDY II 
 
The main objective of study II was to assess the usefulness of the radiobiological 
parameters inherent radiosensitivity, proliferation and number of tumor cells on 
treatment outcome after radiotherapy. A material of head and neck carcinomas was 
used. The hypothesis was that individually measured parameters are better for 
predicting treatment outcome than population averages are. 
 
As stated previously, inherent radiosensitivity expressed as SF, measured with the 
clonogenic assay, correlates with local control (103, 104). However not all studies have 
found the same correlation although they used smaller patient material (136, 137). 
Proliferation has not been firmly demonstrated as an independent prognostic marker of 
treatment outcome (59). The combination of these two parameters, inherent 
radiosensitivity and proliferation, was evaluated in study II in a simple equation 
together with tumor size translated into number of tumor cells. To assess the robustness 
of individually measured radiobiological parameters, these were tested against 
population-derived averages. In the available material we evaluated 18 of 46 patients 
with individual radiobiological parameters measured. These 18 patients remained for an 
extensive analysis after we decided to exclude patients who had received brachytherapy 
since the effect of this treatment was not accounted for in the equation we used. The 
model’s ability to predict treatment outcome after radiotherapy in this material of head 
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and neck carcinoma patients reached borderline significance (p=0.073), using patient-
specific parameters even though only 18 patients remained in the final analysis. 
Both sensitivity and negative predictive value were better (75% versus 38% and 100% 
versus 67%, respectively) when patient-specific parameters were used. Note that the 
predictive values in this study concern local recurrence. Considering, instead, local 
control with a predictive cutoff value of 95% (the same as in study III) gives a 
sensitivity of 40% for both individual and average data. However, both specificity and 
positive predictive value are 100% for patient-specific parameters versus 75% and 
57%, respectively, for population averages. An ROC analysis to compare population 
based versus individually derived radiobiological parameters shows a slightly better 
result using individually measured parameters with AUC = 0.7 versus AUC = 0.6 for 
population-derived parameters in this small patient material. 
 
The reliability of individually measured radiobiological parameters must be addressed. 
Heterogeneity within a tumor is to be expected and can possibly affect the robustness of 
measurements and raise questions regarding how to interpret the results (138). Well 
established and easy-to-use methodologies are essential if they are to be used in clinical 
practice with a high ratio of conclusive results. The inherent radiosensitivity cell-
survival curve of a tissue and the effect after fractionated radiotherapy are reflected in 
the LQ formula by the α/β ratio. Higher values are normally seen in tissues with 
pronounced early side effects after ionizing radiation, which also demonstrates less 
sparing by dose fractionation. This also applies to most carcinomas. We anticipated an 
α/β ratio of 15 in the equations in study II. However this assumption is tentative, albeit 
based on the fact that head and neck carcinomas normally have a high α/β ratio (139). 
We tested different α/β ratios in the equations (table 1) but this did not have any major 
affect on the results. Proliferation was assumed to be equal to Tpot measured before 
radiotherapy (59). This implies that all tumor-cell kill was achieved by radiotherapy. 
This can be questioned especially in fast-growing and radioresistant tumors. Tumor 
cells die from lack of nourishment and oxygen during normal growth conditions. This 
prolongs the tumor doubling time, making the clinical doubling time longer than the 
potential doubling time.  Although it is unlikely that this form of tumor cell death 
ceases as soon as antitumoral treatment is given it is reasonable to assume that as 
tumors regress during therapy a greater extent of tumor kill is gradually achieved by the 
treatment. How fast this process occurs probably depends on several factors such as 
how quickly after radiation the tumor cells die and also the radiosensitivity of the 
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tumor.  The idea of a lag period before onset of accelerated proliferation in tumor cells 
after radiation was not considered in the radiobiology model used (54, 56). Proliferation 
was assumed during the entire course of radiotherapy with a tumor cell doubling time 
represented by Tpot. This might be a weakness of the present work and most studies 
include a lag period when considering proliferation after radiotherapy even if it varies 
in time. However no solid data on the precise length of such a lag period before onset 
of proliferation can be considered to exist, and this is an area where further research is 
warranted. Calculations of TCP using a lag period of three weeks before onset of 
proliferation and an α/β of 15 are, however, presented in table I. 
 
 Table I. Predicted and actual local control in 18 carcinomas of the head and neck for 
different α/β values and depending on whether a lag period before proliferation is 
introduced. 
Patient Q 
α/β=15 
Q 
α/β=10 
Q 
α/β=5 
Q 
α/β=3 
Q 
Tk 22d. 
Local 
Control 
2 0 0 0 0 1.00 Yes 
11 0 0 0 0 0 - 
13 1.00 1.00 1.00 0.98 1.00 Yes 
18 0 0 0 0 0.33 Yes 
20 1.00 1.00 1.00 1.00 1.00 Yes 
24 0.05 0 0 0 1.00 yes 
25 0 0 0 0 0.05 - 
29 0 0 0 0 0 Yes 
33 0 0 0 0 0 Yes 
35 1.00 1.00 1.00 0.54 1.00 Yes 
39 0 0 0 0 0 - 
42 0 0 0 0 0.98 - 
47 0 0 0 0 0.01 - 
50 0 0 0 0 0 - 
54 0.15 0 0 0 0.54 - 
55 0.73 0.35 0 0 0.95 - 
56 0.57 0.06 0 0 0.95 Yes 
57 1.00 1.00 1.00 1.00 1.00 Yes 
Q = Probability of local control where 1 equals 100 % 
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A limited clonogeneity of the tumors is not included in the model but all tumor cells 
were considered as potentially clonogenic. However, to test the model calculations 
were performed considering 10 % of the tumor cells as clonogenic (calculations not 
shown). This did not alter the results considerably. As expected, the probability of local 
control did increase in the tumors with a probability between 5% and 95% in the 
original calculations. Still only one of these patients reached a probability of local 
control above 95%.  
 
Another factor of importance for radiation effect is the oxygenation status of the tumor. 
It has been demonstrated for head and neck carcinomas that oxygen tension in the 
tumor before start of treatment correlates with treatment outcome (67). Whether this is 
an effect of enhanced radioresistance or a more aggressive tumor phenotype is not fully 
understood. An unfavorable effect of hypoxia on radiation effect after a single fraction 
is well established, as presented earlier (11, 140). The oxygen enhancement ratio 
(OER) represents the dose difference required to achieve a certain cell kill when 
oxygen is introduced to anoxic or hypoxic cells. The effect of hypoxia on fractionated 
radiotherapy is more complicated and reoxygenation is an important factor in treatment 
outcome (81). To test the supposed impact of hypoxia on the current results we 
introduced an imaginary fraction of hypoxic cells (10% or 30%) in the tumors. SF was 
then recalculated with an OER of 2 representing the presumed effect of hypoxia in 
these cells. The number of surviving cells in the oxic and hypoxic fractions in each 
tumor was accounted for and the probability of cure was calculated for each tumor with 
10% or 30% of hypoxic cells respectively. The results are presented in table II. As 
shown, even a small fraction of hypoxic cells has theoretically a major impact on 
predicted treatment outcome after fractionated radiation, making it very difficult to 
accomplish complete tumor cell kill and local control. Clinical experience does not, 
however, confirm such an important impact on treatment outcome.  Although a certain 
oxygen effect might be present even in fractionated radiotherapy, it is probably difficult 
to quantify and measure this correctly to fit into an equation. To do so you would 
probably require a model that accounts not only for continuous variations in hypoxia 
levels but also for how large a volume of the tumor is hypoxic at each fraction. 
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Table II. Probability of local control with different ratios of 
tumor hypoxia. 
 
Patient Q, 30 % 
hypoxia 
Q, 10 % 
hypoxia 
Q, Oxic Local 
control 
2 0 0 0 Yes 
11 0 0 0 - 
13 0 0.05 1.00 Yes 
18 0 0 0 Yes 
20 0.94 1.00 1.00 Yes 
24 0 0 0.06 Yes 
25 0 0 0 - 
29 0 0 0 Yes 
33 0 0 0 Yes 
35 0 0 1.00 Yes 
39 0 0 0 - 
42 0 0 0 - 
47 0 0 0 - 
50 0 0 0 - 
54 0 0 0.15 - 
55 0 0 0.72 - 
56 0 0 0.57 Yes 
57 0 0.16 1.00 Yes 
Q= Probability of local control where 1 equals 100 % 
 
The results of study II support the idea that individually measured radiobiology 
parameters are robust enough to be used in models to predict treatment outcome after 
radiotherapy. Further, individual radiobiological measurements are better than 
population-based averages at prediction of treatment outcome after radiotherapy. 
Predictive radiotherapy modeling is an area well merited for further investigation. 
 
4.3 STUDY III 
 
Study III was designed to further evaluate the role of individually measured 
radiobiological parameters in the same material of head and neck carcinomas that was 
presented in paper II. At the same time another mathematical model for evaluating 
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tumor control probability (TCP) based on biologically effective dose (BED) was 
evaluated. This enabled the patients that received brachytherapy to be included in the 
TCP analysis, allowing more data to be evaluated.  
 
Forty-six patients had defined tumor material, with 35 tumors demonstrating local 
control and 11 local relapse. Forty-three patients were evaluable. In three tumors a 
BED could not be defined. In two of these it was negative due to a large proliferation 
coefficient and in the third SF was determined to 1, rendering a definition of α 
impossible. There was a trend towards increasing probability of local control with a 
higher BED both when calculated with tumor-specific radiobiological parameters and 
also when using population average parameters. However when TCP was established 
by introducing number of tumor cells estimated by tumor volume before treatment, the 
two groups appeared to separate more clearly. TCP based on tumor-specific 
radiobiological parameters seems to give a better prediction of actual tumor control 
than corresponding average data, which greatly underestimates cure with less than a 
10% prediction of tumor control. Assuming that a calculated TCP of 95% is the 
threshold for accurate prediction of local tumor control, the sensitivity, the specificity 
and the positive and the negative predictive values of the different approaches for 
calculating the TCP were determined. Sensitivity and specificity for tumor-specific 
parameters were 63% and 80%, respectively. The corresponding values for population-
based averages were 0% and 91%, respectively. Positive predictive value was 92% 
when tumor-specific parameters were used compared to 0 % for population-based. An 
ROC analysis was done to distinguish the predictive values of the different methods of 
establishing TCP (134). The ROC curve obtained, based on patient-specific α and Tpot, 
had an AUC of 0.7 with a p-value of 0.01, showing that the area under the ROC curve 
differed significantly from 0.5. There is therefore evidence that this method is able to 
distinguish between a group of patients presenting local control and a group that does 
not. The same advantageous result was not shown when calculations were based on 
population averages. These resulted in an AUC of 0.5 and consequently a non 
discriminatory p-value. 
 
These results support the idea of combining individual radiobiological data - as in this 
case SF and proliferation - and also of considering number of tumor cells to establish a 
prediction of tumor control. Previous reports have not been able to firmly establish a 
relationship between radiobiological parameters, except that greater T stage and 
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increasing tumor volume indicate worse prognosis (41, 141), and the papers on SF2 
mentioned previously indicate a role of inherent radiosensitivity on local control (103, 
104). The combination of individual data that seems fruitful might be explained by the 
fact that if only one factor is considered the others can interfere as confounders and 
conceal a potential relationship. Note that the relationship between tumor size and local 
control in this material was reversed, with a median tumor volume of 14 cm
3
 when 
local control was achieved compared to 10 cm
3
 in tumors that relapsed. The present 
study result is therefore not likely to merely reflect the impact of tumor size on TCP. 
Some assumptions regarding radiobiological parameters differed in this study from 
those stated in paper II and referred to in the previous chapter. The main reason is that 
numerous recent papers (57, 142-144) have evaluated BED and the possible impact on 
tumor control after treatment. In doing so they used different radiobiological 
assumptions. We used assumptions similar to the ones in those papers regarding α/β 
and proliferation. In general we set tumor α/β to 10 as in a recent paper evaluating head 
and neck carcinomas (57). Those authors also specified a lag period before start of 
proliferation to 22 days and we did the same in the present study. As already stated, no 
definite time point when proliferation should be considered to begin after start of 
radiotherapy is established. One reason for using a lag period is that it might take a 
while before the net proliferation of tumor cells during radiation reaches the Tpot level 
measured before start of radiotherapy - presuming that it in fact does so. This lag period 
would thus account for the uncertainties regarding proliferation during radiotherapy, 
allowing the use of Tpot as a substitute for tumor doubling time – even though Tpot 
might underestimate doubling time after radiotherapy, at least initially. To summarize: 
this study shows that TCP based on BED using individually measured radiobiological 
parameters is superior to TCP based on BED and average radiobiological parameters. 
This further supports the idea of a favorable impact of individually-measured 
radiobiological parameters when predicting outcome after radiotherapy.  
 
4.4 STUDY IV 
 
In study IV the role of the thioredoxin (Trx) - thioredoxin reductase (TrxR) system and 
the cellular redox balance on radioresistance was investigated. A gold(I) compound, 
[Au(SCN)(PEt3)], that selectively inhibits TrxR, was evaluated in a radioresistant cell 
line, U-1810. The effect on radiation sensitivity was assessed as were gene expression 
changes following radiation in combination with the gold compound.  
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The use of gold compounds in clinical practice is an attractive approach since gold is 
readily used in the clinic in inflammatory diseases i.e. rheumatoid arthritis (145). The 
inhibitory effect of the gold(I) compound on expression of TrxR in U1810 was 
confirmed and it decreased by about two-thirds after cultivation with 2.5 µM 
[Au(SCN)(PEt3)] for 24 and 48 hours. Continuous cultivation of U1810 cells in 0.05 
µM gold(I) compound maintained the TrxR at similar low levels. qPCR was used to 
measure the inhibition of siRNA on TrxR mRNA expression and this expression 
decreased over time from 60 % of original values at 24 hours after transfection to 35 % 
at 72 hours. Western blot confirmed an inhibitory effect on TrxR expression at protein 
level. Proliferation of cell line U1810 was not affected after a shorter exposure of up to 
48 hours of the gold(I) compound alone. However, continuous exposure to the lower 
level of 0.05µM seriously affected the ability of the cell line to proliferate. Suppression 
of TrxR with siRNA confirmed this negative effect on long-term cell proliferation. 
In addition, exposure of U1810 cells to ionizing radiation with a single fraction of 2 Gy 
and 5 Gy was evaluated. This radioresistant cell line only demonstrated impaired 
repopulation after exposure to 5 Gy, a dose that also reduced the surviving fraction 
according to the extrapolation method (132). The lower, but perhaps clinically more 
relevant, dose of 2 Gy did not impair surviving fraction or repopulation significantly. 
Radiosensitive cell line U1906, used as a control, was sensitive to both 2 Gy and 5 Gy. 
Exposure to radiation in combination with [Au(SCN)(PEt3)] in U1810 reduced the 
surviving fraction and repopulation rate significantly after 2 Gy as well as after 5 Gy. 
These findings indicate the possibility of sensitizing radioresistant cells to clinically 
relevant doses of radiation by inhibiting TrxR. It would be of great interest to evaluate 
whether normal cells are also sensitized to ionizing radiation by inhibition of TrxR. If 
not, an advantageous therapeutic ratio between tumor cells and surrounding normal 
tissue might be explored. Low levels of ROS have been related to radioresistance and 
depletion of ROS scavengers would consequently sensitize cells to ionizing radiation 
(96). The intracellular redox balance is often altered in malignant cells and the 
expression of Trx - TrxR elevated (95). This suggests that inhibition of TrxR would 
affect malignant cells but not necessarily normal cells in the supporting stroma and 
surrounding tissues, at least not to the same extent, possibly giving a selective tumor 
sensitizing effect to ionizing radiation. The use of flow cytometry showed that exposure 
to the gold(I) compound affected the cell cycling in U1810 cells. Relatively more cells 
traversed the cell cycle into 2
nd
 cycling with a continuously larger fraction associated 
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with longer exposure times. It is possible that this also affects the sensitivity of the cells 
to ionizing radiation with more cells cycling and therefore in potentially more 
radiosensitive cell cycle phases than if they had become quiescent or remained in G1 
(146). However exposure to the gold compound alone did not accelerate proliferation: 
as noted earlier it was unaffected. Instead, with a continuous low exposure, there was 
reduced proliferation. This can seem to contradict the findings on the effect of cell 
cycling. One explanation could be that there was an arrest in finalizing the cell cycle, 
with relative more cells in the ultimate cell cycle phase. Exposure of the gold 
compound alone to the U1810 cell line demonstrated 20 differentially up-regulated 
genes connected to the cell cycle in the gene expression analysis. This is well in line 
with these findings. 
 
The use of gene expression analysis in the clinical setting has yet to be verified. A few 
clinical studies evaluate the importance of gene expression patterns to discriminate 
outcome after radiotherapy in different patients but further clinical evaluations are 
needed before clinical use can be established (147, 148). Gene expression analysis after 
exposure to [Au(SCN)(PEt3)] in combination with radiation demonstrated a much 
stronger effect than exposure to radiation or the TrxR inhibitor alone. 181 genes were 
uniquely up-regulated and 95 down-regulated after the combined treatment. This was 
not seen after exposure to radiation alone or to the gold(I) compound where only a few 
genes were uniquely affected.  The Gene Ontology vocabulary was used for functional 
classification and enrichment testing in order to achieve a more comprehensive survey 
of the affected genes. When these were subjected to enrichment testing using the Gene 
Ontology Tree Machine (GOTM), several GO terms emerged as significantly enriched. 
Four different clusters of related enriched GO categories were identified: DNA- 
damage, repair and replication, DNA and chromatin organization, cell cycle and finally 
cytokine and chemokine activities. These findings correlate well to corresponding 
genes that must be involved in cellular response to ionizing radiation. The interesting 
finding is that only combined treatment gives significant alterations in gene expression. 
This indicates a pronounced effect on cellular response to ionizing radiation when cells 
are treated with the gold(I) compound, which is reflected in the altered repopulation 
and decreased surviving fraction.   
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5 CONCLUSIONS 
 
The present study was performed to investigate the value of using models based on 
radiobiological parameters to predict clinical outcome after radiotherapy and the 
possibility to affect the radiobiological parameter inherent radiosensitivity by altering 
the intracellular redox balance. The following conclusions are made: 
 
Radiobiological models based on inherent radiosensitivity, proliferation and number of 
tumor cells have the possibility to predict clinical outcome after radiotherapy. 
Individual derived radiobiological parameters are better to use than population derived 
averages in predicting clinical outcome after radiotherapy when used in radiobiological 
models. 
 
The radiobiological parameters SF2 and Tpot are robust enough to be used in models to 
predict individual treatment outcome after radiotherapy. 
 
Different models to predict treatment outcome may be used if they consider variations 
in radiobiological parameters between individual tumors. 
 
The findings support the idea of combining different radiobilogical parameters in a 
model to predict clinical outcome after radiotherapy. 
 
Altering the redox balance in tumor cells by inhibition of TrxR reduces the inherent 
radiosensitivity and decreases repopulation after exposure to inonizing radiation. The 
effect on inherent radiosensitivity is supported by gene expression analysis 
demonstrating effect on DNA –damage, -repair, cell cycle and chromatin organization. 
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